GB005

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company's lead program is seralutinib (GB002), an inhaled PDGFR, CSF1R, and c-Kit inhibitor currently in Phase 3 clinical development for the treatment of pulmonary arterial hypertension (PAH). Gossamer Bio was founded by industry veterans with a strategy of building a pipeline of differentiated product candidates that address high unmet medical needs. While the company previously developed GB005 for inflammatory bowel disease, it has since shifted its primary focus toward its pulmonary hypertension franchise.